Developmental attenuation of N-methyl-D-aspartate receptor subunit expression by microRNAs

• Published in: Neural development 2015-09, Vol.10 (1), p.20-20, Article 20
• Main Authors: Corbel, Caroline, Hernandez, Israel, Wu, Bian, Kosik, Kenneth S
• Format: Article
• Language: English
• Subjects: Animals; Animals, Newborn; Aspartate; Blotting, Western; Care and treatment; Development and progression; Gene Expression Regulation - physiology; Glutamate; HEK293 Cells; Hippocampus - growth & development; Hippocampus - metabolism; Humans; Methyl aspartate; MicroRNA; MicroRNAs - genetics; Nervous system diseases; Neural circuitry; Neurogenesis - genetics; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate - biosynthesis; Receptors, N-Methyl-D-Aspartate - genetics; Reverse Transcriptase Polymerase Chain Reaction; Risk factors; Short Report
• ISSN: 1749-8104; 1749-8104
• DOI: 10.1186/s13064-015-0047-5

N-methyl-D-aspartate receptors (NMDARs) are a subtype of ionotropic glutamate receptors and are expressed throughout the central nervous system (CNS). Their activity is required for excitatory synaptic transmission, the developmental refinement of neural circuits and for the expression of many forms of synaptic plasticity. NMDARs are obligate heterotetramers and the expression of their constituent subunits is developmentally and anatomically regulated. In rodent cortex and hippocampus, the GluN2B subunit is expressed at high levels early in development and decreases to plateau levels later while expression of the GluN2A subunit has a concomitant increase. Regulation of GluN2A and GluN2B expressions are incompletely understood. Here, we showed the influence of miRNAs in this process. Two miRNAs, miR-19a and miR-539 can influence the levels of NMDARs subunits, as they target the mRNAs encoding GluN2A and GluN2B respectively. MiR-539 also modified the expression of the transcription factor REST, a known regulator of NMDAR subunit expression. miR-19a and miR-539, in collaboration with REST, serve to set the levels of GluN2A and GluN2B precisely during development. These miRNAs offer an entry point for interventions that affect plasticity and a novel approach to treat neurodegenerative diseases.